EGFR-TKIs在NSCLC中的耐药机制及治疗策略研究进展★

Research progress of the resistance mechanism and reversal strategies of the EGFR-TKIs in NSCLC★

摘要:

表皮生长因子受体（EGFR）抑制剂是目前临床治疗非小细胞肺癌（NSCLC）的一线小分子靶向药物，随着EGFR酪氨酸激酶抑制剂（EGFR-TKI）的广泛使用，其耐药现象也日趋明显，已成为其治疗NSCLC的巨大挑战。本文总结了EGFR-TKIs在NSCLC中的主要耐药机制，并对相关逆转策略的研究进展进行综述。

Abstract:

Epidermal growth factor receptor (EGFR) inhibitors are currently the first-line small molecule-targeted drugs commonly used in the treatment of non-small cell lung cancer (NSCLC). However, drug resistance inevitably developed after long time exposure of the EGFR tyrosine kinase inhibitors (EGFR-TKI), which has become a great challenge in the treatment of NSCLC. In this paper, we summarized the mechanisms of drug resistance of EGFR-TKIs in the treatment of NSCLC and reviewed the research progress of relevant reversal strategies.